Edition:
United Kingdom

DaVita Inc (DVA.N)

DVA.N on New York Stock Exchange

57.70USD
16 Jul 2019
Change (% chg)

$0.75 (+1.32%)
Prev Close
$56.95
Open
$56.95
Day's High
$58.42
Day's Low
$56.95
Volume
333,221
Avg. Vol
397,117
52-wk High
$79.02
52-wk Low
$43.40

Latest Key Developments (Source: Significant Developments)

Davita Statement On Advancing American Kidney Health
Wednesday, 10 Jul 2019 

July 10 (Reuters) - DaVita Inc ::DAVITA STATEMENT ON ADVANCING AMERICAN KIDNEY HEALTH.DAVITA KIDNEY CARE SAYS "APPRECIATES PRESIDENT TRUMP, THE ADMINISTRATION AND SECRETARY AZAR FOR TAKING STEPS TO IMPROVE THE LIVES OF KIDNEY PATIENTS".  Full Article

DaVita Reports Q1 Revenue Of $2.74 Billion
Tuesday, 7 May 2019 

May 7 (Reuters) - DaVita Inc ::QTRLY EARNINGS PER SHARE $0.90.1ST QUARTER 2019 RESULTS.Q1 REVENUE $2.743 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.82 BILLION.DAVITA- TOTAL U.S. DIALYSIS TREATMENTS FOR Q1 WERE 7,297,460, OR 95,267 TREATMENTS PER DAY, REPRESENTING A PER DAY INCREASE OF 2.9% OVER THE Q1 OF 2018.QTRLY ADJUSTED EARNINGS PER SHARE $0.91.SEES 2019 OPERATING CASH FLOW FROM CONTINUING OPERATIONS IN THE RANGE OF $1,375 MILLION TO $1,575 MILLION.QTRLY EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.72.SEES 2019 CAPITAL EXPENDITURES FROM CONTINUING OPERATIONS IN THE RANGE OF $800 MILLION TO $840 MILLION.Q1 EARNINGS PER SHARE VIEW $0.93 -- REFINITIV IBES DATA.SEES 2019 ADJUSTED CONSOLIDATED OPERATING INCOME $1,540 MILLION TO $1,640 MILLION.  Full Article

Davita Says Total Compensation For CEO Was About $32 Mln In 2018 Versus $15.3 Mln In 2017
Monday, 29 Apr 2019 

April 29 (Reuters) - DaVita Inc ::DAVITA INC - TOTAL COMPENSATION FOR CEO KENT J. THIRY WAS ABOUT $32 MILLION IN 2018 VERSUS $15.3 MILLION IN 2017.DAVITA INC - TOTAL COMPENSATION FOR CFO JOEL ACKERMAN WAS $6.6 MILLION IN 2018 VERSUS $4.7 MILLION IN 2017.DAVITA INC - RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL TEAMMATES IS ESTIMATED TO BE 526 TO 1.  Full Article

DaVita Inc. Reports Q3 Revenue of $2.847 Billion
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - DaVita Inc ::3RD QUARTER 2018 RESULTS.Q3 REVENUE $2.847 BILLION VERSUS I/B/E/S VIEW $2.93 BILLION.DAVITA -TOTAL U.S. DIALYSIS TREATMENTS FOR Q3 2018 WERE 7,377,277, OR 94,580 TREATMENTS PER DAY, REPRESENTING PER DAY INCREASE OF 4.0% OVER Q3 2017.EXPECT OPERATING CASH FLOW FROM CONTINUING OPERATIONS FOR 2018 TO BE IN RANGE OF $1.4 BILLION TO $1.6 BILLION.QTRLY LOSS PER SHARE $0.82.Q3 EARNINGS PER SHARE VIEW $0.87, REVENUE VIEW $2.93 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

NephroPlus Acquires DaVita Care India
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - NEPHROPLUS::NEPHROPLUS ACQUIRES DAVITA CARE INDIA.  Full Article

DaVita Reports Q1 Earnings Per Share $1.05 From Continuing Operations
Thursday, 3 May 2018 

May 3 (Reuters) - DaVita Inc ::DAVITA INC 1ST QUARTER 2018 RESULTS.Q1 EARNINGS PER SHARE $1.05 FROM CONTINUING OPERATIONS.Q1 EARNINGS PER SHARE VIEW $0.93 -- THOMSON REUTERS I/B/E/S.TOTAL U.S. DIALYSIS TREATMENTS FOR Q1 OF 2018 WERE 7,174,026, OR 92,568 TREATMENTS PER DAY, A PER DAY INCREASE OF 4.8 PERCENT.QTRLY TOTAL REVENUE $2.85 BILLION VERSUS. $2.63 BILLION.  Full Article

DaVita Received Second Request For Additional Information From U.S. FTC
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Davita Inc ::DAVITA SAYS ON MARCH 12, RECEIVED SECOND REQUEST FOR ADDITIONAL INFORMATION AND DOCUMENTARY MATERIAL FROM U.S. FEDERAL TRADE COMMISSION - SEC FILING.DAVITA - ‍SECOND REQUEST EXTENDS WAITING PERIOD IMPOSED BY ACT UNTIL 30 DAYS AFTER DAVITA AND BUYER HAVE SUBSTANTIALLY COMPLIED WITH SECOND REQUEST​.DAVITA - FTC SENT SECOND REQUEST AS PER HART-SCOTT-RODINO ANTITRUST IMPROVEMENTS ACT IN CONNECTION WITH FTC'S REVIEW OF CO'S PENDING DEAL WITH OPTUM.DAVITA - CO CONTINUES TO EXPECT THAT PENDING DEAL WITH OPTUM WILL CLOSE IN 2018.  Full Article

Davita Inc Reports Q4 Earnings Per Share $0.85 From Continuing Operations
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Davita Inc ::4TH QUARTER 2017 RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.92 FROM CONTINUING OPERATIONS.Q4 EARNINGS PER SHARE $0.85 FROM CONTINUING OPERATIONS.DAVITA- IN QUARTER, RECOGNIZED A NON-CASH OTHER-THAN-TEMPORARY IMPAIRMENT CHARGE OF $280 MILLION ON INVESTMENT IN ASIA PACIFIC JOINT VENTURE.‍AS A RESULT OF RECENT U.S. TAX REFORM LEGISLATION, RECORDED A REDUCTION IN TAX EXPENSE OF $252 MILLION FOR QUARTER AND YEAR ENDED DECEMBER 31.‍STILL EXPECT OUR KIDNEY CARE CONSOLIDATED OPERATING INCOME FOR 2018 TO BE IN RANGE OF $1.5 BILLION TO $1.6 BILLION​.‍EXPECT OPERATING CASH FLOW FROM CONTINUING OPERATIONS FOR 2018 TO BE IN RANGE OF $1.4 BILLION TO $1.6 BILLION​.TOTAL U.S. DIALYSIS TREATMENTS FOR Q4 WERE 7.2 MILLION OR 92,287 TREATMENTS PER DAY, REPRESENTING A PER DAY INCREASE OF 5.8% OVER Q4 OF 2016.Q4 EARNINGS PER SHARE VIEW $0.94 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL NET REVENUES $2.78 BILLION VERSUS $2.7 BILLION LAST YEAR.Q4 REVENUE VIEW $3.89 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

DaVita Says Size Of Board Will Be Reduced From 11 To 10 Members
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Davita Inc ::DAVITA SAYS ON FEB 1, BOARD ADOPTED RESOLUTIONS THAT PROVIDE THAT SIZE OF BOARD WILL BE REDUCED FROM 11 TO 10 MEMBERS - SEC FILING.  Full Article

The Everett Clinic Announces Senior Leadership Transitions
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - The Everett Clinic::THE EVERETT CLINIC ANNOUNCES SENIOR LEADERSHIP TRANSITIONS.THE EVERETT CLINIC SAYS EFFECTIVE JAN 31, ITS CEO AND MARKET PRESIDENT, RICK COOPER, WILL RETIRE AND ARIC COFFMAN WILL REPLACE COOPER.  Full Article

UPDATE 3-Trump administration pushes U.S. at-home kidney care, transplant availability

NEW YORK/WASHINGTON, July 10 The Trump administration on Wednesday set goals to move more kidney disease treatment into patients' homes and increase transplants while reducing the U.S. reliance on more costly dialysis clinics.